ZyVersa Therapeutics announces publication of data on inflammasome ASC

ZyVersa Therapeutics announces that inflammasome researchers from the University of Miami Miller School of Medicine and inventors of Inflammasome ASC Inhibitor IC 100 have published a scientific paper in the peer-reviewed International Journal of Molecular Sciences demonstrating that plasma levels of inflammasome ASC show promise as a biomarker of early cognitive decline in older adults. The paper titled, The Inflammasome Adaptor Protein ASC in Plasma as a Biomarker of Early Cognitive Changes, summarizes biomarker assessments in older adults at baseline and at one-year follow-up. Following is a summary of key findings: Plasma ASC levels were elevated in older adults who were cognitively normal at baseline but demonstrated cognitive decline one year later compared to ASC levels in those who remained cognitively normal one-year post-baseline assessment. The increase in ASC levels was even higher in people who were 70 years or older. Likewise, plasma ASC levels in the NI group were elevated compared to ASC levels in older adults who demonstrated cognitive impairment at both baseline and one year later, indicating that plasma ASC levels are increased in the early stages of cognitive decline. Again, the increase in ASC levels was even higher in people who were 70 years or older. In the group over 70 years old, area under the curve for plasma levels of ASC in group NI versus group NN was 0.81, indicating excellent ability to differentiate between people with cognitive decline at one year versus those who were cognitively normal both at baseline and at one year. AUC is used to determine the diagnostic power of a biomarker.